Noël Wathion was instrumental in steering the European Medicines Agency successfully through periods of particular challenge such as Brexit and COVID-19, the EMA says.
The tasks of the deputy executive director’s office at the European Medicines Agency are being redistributed within the agency following the retirement this week of Noël Wathion, who held the second-in-command post during the last five or so years of his 25 years at the EMA.
Wathion, who joined the EMA in 1996, retired on 30 June. He has occupied many different roles and responsibilities at...
<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>
As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.
<p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>
A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.
With the deadline for comments on the US FDA’s draft guidance less than a month away, the Pink Sheet offers an infographic outlining what the agency is expecting in diversity action plans and when that might be implemented.
